Silmitasertib (CX-4945)

For research use only.

Catalog No.S2248

67 publications

Silmitasertib (CX-4945) Chemical Structure

CAS No. 1009820-21-6

Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Silmitasertib induces autophagy and promotes apoptosis. Phase 1/2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 291 In stock
USD 127 In stock
USD 170 In stock
USD 320 In stock
USD 890 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Silmitasertib (CX-4945) has been cited by 67 publications

Purity & Quality Control

Choose Selective Casein Kinase Inhibitors

Biological Activity

Description Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Silmitasertib induces autophagy and promotes apoptosis. Phase 1/2.
Features First clinical inhibitor of CK2.
Targets
CK2 [1]
(Cell-free assay)
1 nM
In vitro

CX-4945 is selective for CK2, as it only inhibits 7 of the 238 kinases by more than 90% at concentration of 0.5 μM, which is 500-fold greater than the IC50 of CK2. Although in cell-free systems CX-4945 inhibits FLT3, PIM1, and CDK1 with IC50 of 35 nM, 46 nM, and 56 nM, respectively, CX-4945 treatment at 10 μM is inactive against FLT3, PIM1, and CDK1 in cell-based functional assays. CX-4945 exhibits a broad spectrum of antiproliferative activity, and the breast cancer cell lines displays the widest range of sensitivity to CX-4945 with EC50 of 1.71-20.01 μM. The antiproliferative activity of CX-4945 correlates with CK2α mRNA and protein levels but not the CK2α' catalytic subunit, the regulatory CK2β subunit, and the PI3K/Akt or PTEN mutational status. CX-4945 inhibits PI3K/Akt signaling by directly blocking the phosphorylation of Akt at Serine 129 by CK2 rather than through activation of PTEN. CX-4945 treatment causes reduced phosphorylation of p21 (T145), increased levels of total p21 and p27, and induction of caspase 3/7 activity. CX-4945 treatment induces a G2/M cell-cycle arrest in BT-474 cells and a G1 arrest in BxPC-3 cells. CX-4945 inhibits HUVEC proliferation, migration, and tube formation with IC50 of 5.5 μM, 2 μM, and 4 μM, respectively. Under hypoxic conditions in BT-474 and BxPC-3 cells, CX-4945 treatment prevents downregulation of p53 and pVHL and reduces activation of HIF-1α transcription. [1] CX-4945 potently inhibits endogenous intracellular CK2 activity with IC50 of 0.1 μM in Jurkat cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
platelets NY\6W2ZkU2mwYYPlJGF{e2G7 MUCxM|UwOTBizszN MViwMlUhcA>? Ml3nSG1UVw>? NHXZVGxz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJkh[W6mIIDsZZRmdGW2IHHn[5Jm\2G2aX;u NIDYRVczPjN6MUSzOy=>
HDMEC MVHLbY5ie2ViQYPzZZk> NHfrTZIxNjJ3L{CuOU8yKM7:TR?= M{nrNlI1KGh? MljzSG1UVw>? M3LFfJJm\HWlZYOgR2szKGurbnHz[UBi[3Srdnn0fUwhfleIIHX4dJJme3Orb36gZY5lKHOnY4LleIlwdg>? Ml\rNlY{QDF2M{e=
HDMEC MV3GeY5kfGmxbjDBd5NigQ>? M1vwXFAvOjVxMD61M|Eh|ryP MU[yOEBp NVPUZVl{TE2VTx?= M1uxdZJm\HWlZYOg[ZhxemW|c3nvckBw\iCYQ1HNMVEh[nW2IH7veEBKS0GPLUG= MkDDNlY{QDF2M{e=
HDMEC MWHGeY5kfGmxbjDBd5NigQ>? NIWyfZMyKM7:TR?= MoroNlQhcA>? Mn[5SG1UVw>? M{\BfYFn\mWldIOgd5Vj[2WubIXsZZIhdG:lYXzpfoF1cW:wIH;mJG5HSVSlMTDhcoQheGixc4Doc{1xPjV? MYmyOlM5OTR|Nx?=
A549  NIro[2RHfW6ldHnvckBCe3OjeR?= NV\xfHJOOy9zMNMg{txO MWK0PEBp M2fGT5N2eHC{ZYPz[ZMhfGinIH3pZ5JweGmubHHyMYlv\HWlZXSg[ZhxemW|c3nvckBw\iCyLV\BTy=> M{HTeVI3OzF6OECw
HDMEC MnTnT4lv[XOnIFHzd4F6 NGG4N|gyNTVyIN88US=> NUG5b3Q1PSCq MWLEUXNQ M2C5eoRm[3KnYYPld{BEUzJia3nuZZNmKGGldHn2bZR6KHerdHjveZQh[W[oZXP0bY5oKGOnbHygeoli[mmuaYT5 NXr2d5pmOjZzOEm1PFY>
HDMEC M{fzdWZ2dmO2aX;uJGF{e2G7 M13TOFUxKM7:TR?= NUeyNlc{OS93IHi= NWn3W2w5TE2VTx?= NXziTldx\GWlcnXhd4V{KHSqZTDueYNt\WG{IIPp[45idCCxZjDwbI9{eGixconsZZRm\CCyNkWgbY4hXE6ILd8xMZN1cW23bHH0[YQhUESPRVRCpC=> NXfp[oJmOjZzOEm1PFY>
HEK293 NIjibGVMcW6jc3WgRZN{[Xl? Ml\rNE42yqEQvF2= NUDlbVVSOTVibXnu MkfKSG1UVw>? NVjh[HU5emWmdXPld{BEUzJia3nuZZNmKGGldHn2bZR6 MkjLNlU5QDd4Mk[=
Hela Mn3yT4lv[XOnIFHzd4F6 MUWwMlXDqM7:TR?= NIjSV4UyPSCvaX6= MnPMSG1UVw>? MVny[YR2[2W|IFPLNkBscW6jc3WgZYN1cX[rdIm= MVuyOVg5PzZ{Nh?=
LAMA84 NIfIeYhMcW6jc3WgRZN{[Xl? M1\W[lAvPcLizszN MmXPNVUhdWmw MmqzSG1UVw>? MkPGdoVlfWOnczDDT|Ihc2mwYYPlJIFkfGm4aYT5 M3;ZUVI2QDh5NkK2
HEK293 M3G0emZ2dmO2aX;uJGF{e2G7 Ml;LN{DPxE1? Ml3wOUBp MnTiSG1UVw>? NGj1SpNEUzJicHjvd5Bpd3K7bHH0[ZMh\UmIM3qgZZQhW2W{MUK3 MX[yOVg5PzZ{Nh?=
UM-SCC1 M3yw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhNE4yNTNyIN88US=> MWexMVUh\A>? MUnJR|UxRTRwMTFOwG0> NFr3T2UzPTd7OEC2NS=>
UM-SCC46 M4fPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLGNE4yNTNyIN88US=> NHvSc5cyNTViZB?= Mnv2TWM2OD1|LkSg{txO MmnxNlU4QThyNkG=
UM-SCC1 NVvub|JETnWwY4Tpc44hSXO|YYm= MVqwMlUwPC9zMDFOwG0> M1zETFczKGh? NW[5dYYy\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gUmYuzLiELDDCZ4wuYExiYX7kJJVxNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCyNUOsJJAzOSxiQWCtNUBidmRiSVytPEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MXiyOVc6QDB4MR?=
UM-SCC46 MUnGeY5kfGmxbjDBd5NigQ>? MmTpNE42NzRxMUCg{txO NE[w[|A4OiCq NETkdFVld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDOSk3FwEJuIFLjcE1ZVCxicEWzMEBxOjFuIFHQMVEh[W6mIIXwMZJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDJUE05KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MWqyOVc6QDB4MR?=
NU-DUL NXPRXYk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLZXoduPS1{NTFOwG0> NWX0RoxpPDhiaB?= NUC5T|VxcW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>? NGKzbXYzPTd6OEK2PS=>
Oci Ly 3 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK0bXF[PS1{NTFOwG0> MUW0PEBp M1HVdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MkfCNlU4QDh{Nkm=
Oci Ly 10 M3\4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO1MVI2KM7:TR?= NXntOVY5PDhiaB?= M1\lPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MWKyOVc5QDJ4OR?=
Oci Ly 1 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjKWWE2NTJ3IN88US=> MmDlOFghcA>? M2nPOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NIW3TGczPTd6OEK2PS=>
Oci Ly 18 M4LHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG1MVI2KM7:TR?= MoLPOFghcA>? M2L3UolvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NVu4clVTOjV5OEiyOlk>
Oci Ly 19  NGD4eWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4S3g3PS1{NTFOwG0> MVy0PEBp Mlf0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> MYCyOVc5QDJ4OR?=
Raji M3nUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LmZ|UuOjVizszN MUm0PEBp MnzxbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> M3jaTVI2Pzh6Mk[5
H1299 NG\4W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxM|UwOTBizszN NYLkVJJqPzJiaB?= MYjpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MXiyOVc2ODNyOB?=
Calu-1  NF\iVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfQTGNpOS93L{GwJO69VQ>? MYG3NkBp NWTVeZlucW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>? MV6yOVc2ODNyOB?=
H358 NUjjNIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxM|UwOTBizszN M3\5NFczKGh? NGi3ZWZqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MUiyOVc2ODNyOB?=
H1299 Mm\jRZBweHSxc3nzJGF{e2G7 M1Tzc|ExKM7:TR?= M4L5VlczKGh? MlG3bY5lfWOnczDhdI9xfG:|aYO= MWqyOVc2ODNyOB?=
Calu-1  M3n1NWFxd3C2b4Ppd{BCe3OjeR?= Mk\jNVAh|ryP MkTPO|IhcA>? M3TGcYlv\HWlZYOgZZBweHSxc3nz M2\yblI2PzVyM{C4
H358 MYDBdI9xfG:|aYOgRZN{[Xl? NIXyW|kyOCEQvF2= MknlO|IhcA>? MoHobY5lfWOnczDhdI9xfG:|aYO= M1LoW|I2PzVyM{C4
PC9/GR NFPBR|NHfW6ldHnvckBCe3OjeR?= NHrCTY42KML3TR?= MV60PEBp MkPEbY5lfWOnczDheZRweGijZ4m= NXWwOYJKOjV2OE[0NFk>
PC9/ER MYfGeY5kfGmxbjDBd5NigQ>? M2mwRlUhyrWP MlrZOFghcA>? MkTrbY5lfWOnczDheZRweGijZ4m= Ml;kNlU1QDZ2MEm=
H28 NGTRPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLwO2sxNjBzLUOwJO69VQ>? Mk\NO|IhcA>? MlzBSG1UVw>? NYLOW2lUUUN3ME23MlIh|ryP NHnKPIwzPTR{MkC4NS=>
H2052 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICzNm4xNjBzLUOwJO69VQ>? MnXLO|IhcA>? NWC0PFBQTE2VTx?= MnXvTWM2OD1{LkCg{txO NWPt[3BZOjV2MkKwPFE>
UM-SCC-1 MlvyR4xwdm:pZX7pZ{BCe3OjeR?= M4LuOFAvPS13IN88US=> NXG0XpV2OTRiZB?= MVLEUXNQ NUCzW4lOyqCrbnjpZol1eyClbH;uc4dmdmmlIIP1dpZqfmGuIHHu[EB{eGincnWg[o9zdWG2aX;u Mn;VNlU{PzlyMU[=
UM-SCC-46 M2jJS2Ntd26xZ3XubYMhSXO|YYm= NIrQSlQxNjVvNTFOwG0> NIW5OWoyPCCm NYrjfXVETE2VTx?= NFXvPWPDqGmwaHnibZR{KGOub37v[4VvcWNic4Xyeol3[WxiYX7kJJNxcGW{ZTDmc5Ju[XSrb36= MnTsNlU{PzlyMU[=
U87-MG NUfSU5RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\KfG9XOS93L{GwJO69VQ>? MYmyOE81QC95MjDo Mk\oSG1UVw>? MU\pcohq[mm2czDj[YxtKGe{b4f0bEBjd3SqIHPvcoNmdnS{YYTpc44h[W6mIITpcYUh\GWyZX7k[Y51dHl? M3vLe|I2OjRzOEm3
MDA-MB-231 NIXlXo5HfW6ldHnvckBCe3OjeR?= M3\SdlIwPS9zMDFOwG0> M4nuPFQhcA>? MULk[YNz\WG|ZYOgeIhmKGOxboP0bZR2fGm4ZTDwbI9{eGixconsZZRqd25ib3[gZo91cCBicD3TOVI6NXB4NTDhcoQheC2VMUK5MWFsfA>? MUGyOVE2Ozd{NR?=
MDA-MB-231 NI\TO5ZHfW6ldHnvckBCe3OjeR?= NV\5O3dsOi93L{GwJO69VQ>? NV;PSFN2PCCq MonVbY5pcWKrdIOgd4VzcW6nIEWyPUBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDlfJBz\XO|aX;uJI9nKEmOLU[sJGlNNTh? NHfqVFEzPTF3M{eyOS=>
ARPE-19 MkHjT4lv[XOnIFHzd4F6 M1j0S|UwOTBxMkCg{txO MUiyOE81QCCq NH7reGVqdmirYnn0d{BEUzJia3nuZZNmKGGldHn2bZR6KGG2IHGgZ49v[2WwdILheIlwdiCxZjC1xsDPxE1? MV2yOFY5PjB6MB?=
ARPE-19 NVO4eYpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHi[lUyOCEQvF2= NGHVe5MzPC17NjDo NW\RNWplTE2VTx?= NX;mUI1ycW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MUiyOFY5PjB6MB?=
HCT116  NGS5VW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTnOmE{OTBizszN M2fIVVI1NTl4IHi= MX\EUXNQ NV73d|JMcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MYOyOFY5PjB6MB?=
ARPE-19 NYG3bYNOTnWwY4Tpc44hSXO|YYm= MmHTNVAh|ryP M{HvflQhcA>? NFLPfFZFVVOR NIfFU2pk[XW|ZYOgSXIue3S{ZYPzJJJme3CxboPlJI93\XJidHjlJJAu\UmIMt8xJIJz[W6laDygZpV1KGSxZYOgco91KGmwZIXj[UBEUE:SwrC= MmDWNlQ3QDZyOEC=
HCT116  MVXGeY5kfGmxbjDBd5NigQ>? NYDBV45FOTBizszN MoPFOEBp NYeyS2FMTE2VTx?= MYTjZZV{\XNiRWKtd5Rz\XO|IILld5BwdnOnIH;2[ZIhfGinIICt[WlHOs7zIHLyZY5kcCxiYoX0JIRw\XNibn;0JIlv\HWlZTDDTG9RyqB? NVy4[ZJDOjR4OE[wPFA>
HCT116  NGXZdItCeG:ydH;zbZMhSXO|YYm= NFLm[4EyOCEQvF2= MmDnNlQwPDhiaB?= NEPMPWFFVVOR MU\pcoR2[2W|IHHwc5B1d3Orcx?= NX;FbpVGOjR4OE[wPFA>
Nalm6  NXHifW1[TnWwY4Tpc44hSXO|YYm= NG\1epcyOC9{MDFOwG0> NVTFbWVUOjRiaB?= M37Qe5Jme3WudIOgbY4h\GWlcnXhd4VlKFCWRV6gdIhwe3Cqb4L5cIF1cW:wIHH0JJRp\SCFS{KgeIFz\2W2IILld4llfWViU{O4NEBidmRiY3;uZ49ucXSjboSg[I94dnKnZ4XsZZRqd25ib3[gVHRGViCycn;0[YlvKGW6cILld5Nqd25? MlnuNlQ2PjF5OUK=
SUP-B15 MYDGeY5kfGmxbjDBd5NigQ>? MUOxNE8zOCEQvF2= M{W5XVI1KGh? MnvLdoV{fWy2czDpckBl\WO{ZXHz[YQhWFSHTjDwbI9{eGixconsZZRqd25iYYSgeIhmKEONMjD0ZZJo\XRicnXzbYR2\SCVM{iwJIFv\CClb37jc41qfGGwdDDkc5dvemWpdXzheIlwdiCxZjDQWGVPKHC{b4TlbY4h\XiycnXzd4lwdg>? MV6yOFU3OTd7Mh?=
Nalm6  NU\VXplzSXCxcITvd4l{KEG|c3H5 NGLLd5A3NzFyIN88US=> M{K5NFQ5KGh? M3HaTolv\HWlZYOgZZBweHSxc3nz M1nlV|I1PTZzN{my
SUP-B15 Moi4RZBweHSxc3nzJGF{e2G7 NUP5SFVjPi9zMDFOwG0> NH;pWXo1QCCq NUWxXZlncW6mdXPld{BieG:ydH;zbZM> NYXtZXN2OjR3NkG3PVI>
C2C12 MmnPSpVv[3Srb36gRZN{[Xl? M17vb|Mh|ryP NYfFRVRTOTJxMkSvOFghcA>? MWjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDvd5Rmd2OuYYP0JIRq\m[ncnXueIlifGmxbjDtZZJs\XK|IHHu[EBCc3RicHjvd5Bpd3K7bHH0bY9v M4XmN|I1Ojl|MEGx
Jurkat NUnhTlhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[4eIg6OS1zMDFOwG0> MXy0PEBp NVzObXpKUUN3ME20Mlkh|ryP NXTQOGR7OjR{NUOwNlQ>
CEM-R NYXZdFd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vEZlEuOTBizszN MX[0PEBp MWfJR|UxRTRizszN NV[2TZJwOjR{NUOwNlQ>
CEM-S NEeydWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnDNU0yOCEQvF2= NX7XR3Z1PDhiaB?= NHjHZWJKSzVyPUSuOkDPxE1? MVeyOFI2OzB{NB?=
MOLT-4 NHnpT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTYNU0yOCEQvF2= M3u1WlQ5KGh? MXLJR|UxRTVwNzFOwG0> NEPWRXkzPDJ3M{CyOC=>
PF-382 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XSO|EuOTBizszN NX\WdVZsPDhiaB?= NWr1XFV1UUN3ME20MlUh|ryP MoLyNlQzPTNyMkS=
ALL-SIL MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XFVVEuOTBizszN NGLzR|k1QCCq NWjnSIo3UUN3ME21Mlch|ryP NX3RTXJrOjR{NUOwNlQ>
HPB-ALL MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTpWIZEOS1zMDFOwG0> NYi0Z3EyPDhiaB?= M3nBU2lEPTB;Nj6xJO69VQ>? NGXINlAzPDJ3M{CyOC=>
DND-41 NWTMcnlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGxMVExKM7:TR?= M3myVVQ5KGh? MlG3TWM2OD17IN88US=> NEnNfWMzPDJ3M{CyOC=>
ALL-SIL Mke2RZBweHSxc3nzJGF{e2G7 NYLwdYZSPSEQvF2= M3ztUVI1NzR6IHi= MWnpcoR2[2W|IHHwc5B1d3Orcx?= NWHGW2U4OjR{NUOwNlQ>
DND-41 MknFRZBweHSxc3nzJGF{e2G7 NVLzcGN7PSEQvF2= MmHSNlQwPDhiaB?= NHyyeWVqdmS3Y3XzJIFxd3C2b4Ppdy=> NIX0[FEzPDJ3M{CyOC=>
MOLT-4 NV\OTnZOSXCxcITvd4l{KEG|c3H5 MnHvOUDPxE1? M4e0U|I1NzR6IHi= MkDxbY5lfWOnczDhdI9xfG:|aYO= MWeyOFI2OzB{NB?=
U-266 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vaXFAuPDBizszN NWrXfXprPDhiaB?= NFjGfmFKSzVyPUG5MlghyrWPwrC= M3y5VVI1ODh4NEm0
INA-6 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfFNE01OCEQvF2= NGjWbpM1QCCq MlnZTWM2OD1{LkSyJOK2VQ>? MYOyOFA5PjR7NB?=
Jeko-1 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rLU|AuPDBizszN NWPscY03PDhiaB?= M2HyOWlEPTB;Mj60JOK2VcLi NGLpVJMzPDB6NkS5OC=>
Rec-1 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmwMVQxKM7:TR?= NVHwcnJ{PDhiaB?= MUDJR|UxRTFwNE[gxtVOyqB? MofuNlQxQDZ2OUS=
A549 M{eyV2Z2dmO2aX;uJGF{e2G7 NUHhOIF{OTBizszN M3XzWlEzNzJ2L{S4JIg> MlLkbY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIH3p[5JifGmxbjDhcoQhcW64YYPpc44> NUXWfJZkOjRyMkO5N|g>
A549 NFzUVFlHfW6ldHnvckBCe3OjeR?= M3f1TVMh|ryP NFP2Zms1QCCq MkjFbY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YhW22jZDDhcoQh\XiycnXzd4lwdiCxZjDTcoFqdCCjbnSgWJdqe3R? Mn35NlQxOjN7M{i=
S-LAMA84 NIfEeGdHfW6ldHnvckBCe3OjeR?= M3XseVPDqM7:TR?= NWD1W4Z2OjRiaB?= NUDMR2xuTE2VTx?= NWHWU2VJemWmdXPld{BEUzJiYXP0bZZqfHl? MnmwNlQxOTJzMEm=
R-LAMA84 NEfOSFdHfW6ldHnvckBCe3OjeR?= MVmzxsDPxE1? MUiyOEBp MVvEUXNQ M1\aZ5Jm\HWlZYOgR2szKGGldHn2bZR6 NFr1XI0zPDBzMkGwPS=>
S-LAMA84 M33IWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeyRWgzNjVvMUCg{txO NF7GS3E1QCCq MljoSG1UVw>? M4W0UYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MXGyOFAyOjFyOR?=
R-LAMA84 NIPtVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6yMlUuOTBizszN Mmr6OFghcA>? NWftclRvTE2VTx?= NUntbXVHcW6qaXLpeJMh[2WubDDndo94fGhiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpRtgQ>? NVzyN2ZqOjRyMUKxNFk>
A549 NETiUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMVMxKM7:TR?= M2jVNFczKGh? M3TZbmROW09? M3zzOmlEPTB;ND6xOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= M2nj[FI{PjVzNESz
H1299 NYjjdGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnYWVYxNTNyIN88US=> MXW3NkBp M13YUmROW09? M3;VR2lEPTB;MT64NEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MmLoNlM3PTF2NEO=
A549 MWDGeY5kfGmxbjDBd5NigQ>? M1niSFEwOTBizszN NEX1[441QCCq M{\leGROW09? NX6yUlNKdGWjZIOgeI8h[SCmb4PlMYRmeGWwZHXueEBl\WO{ZXHz[UBqdiCQb4TjbEBz\XCxcoTldkBi[3Srdnn0fS=> NID3[24zOzZ3MUS0Ny=>
LNCap NH3GWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16xVVAuOzBizszN NF;qcpA1KGR? MXLJR|UxRTRwNUpCpO69VQ>? NE\OVI0zOjh|MkOxOi=>
A431  M3TQOWZ2dmO2aX;uJGF{e2G7 MVGxNEDPxE1? MnGzN|AhdWmw NVjOfFg5[XS2ZX71ZZRmeyCSSUPLMWFsfC2vVF;SJJNq\26jbHnu[y=> M1O3fVIzOzh5OUi4
H2170  MWHGeY5kfGmxbjDBd5NigQ>? NIfMZ4EyOCEQvF2= MWSzNEBucW5? M2P4coF1fGWwdXH0[ZMhWEl|Sz3Bb5QudVSRUjDzbYdv[Wyrbne= NHfJPVYzOjN6N{m4PC=>
A431  NI\nfFFHfW6ldHnvckBCe3OjeR?= MnXrNVAh|ryP M36welQuOjRiaB?= NInUUoNmdmijbnPld{BieG:ydH;zbZMhf2m2aDDldoxwfGmwaXK= NIXoUWYzOjN6N{m4PC=>
H2170  MXXGeY5kfGmxbjDBd5NigQ>? M1e4b|ExKM7:TR?= MWG0MVI1KGh? M2To[YVvcGGwY3XzJIFxd3C2b4Ppd{B4cXSqIHXycI91cW6rYh?= MkDMNlI{QDd7OEi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-S6K1(T389) / S6K1 / p-S6(S235/236) / S6; 

PubMed: 30683840     


DLD-1 cells were incubated with 25 μM silmitasertib for 16 h. The levels of the indicated proteins were analyzed by western blot.

p-AKT(S129) / p-AKT(T308) / p-AKT(S473) / AKT / p-ERK / ERK / TP53 / p-p21(Th145) / p21 / Bcl-xl; 

PubMed: 25798061     


CX-4945 altered PI3K/AKT/Bcl-XL, ERK/AP-1 and TP53/p21proteins in HNSCC. UM-SCC-1 (left) and UM-SCC-46 (right) cell lines were treated with 4 and 10 μM CX-4945, whole cell lysates were harvested 6 and 24 hours after treatment, and subjected to SDS-PAGE and Western blot of indicated proteins. β-action was used as a loading control.

p-Smad2 (Cytosol) / Smad2/3 (Cytosol) / Smad2/3 (Nucleus) / Twist / Snail; 

PubMed: 24023938     


The effect of CX-4945 on TGF-β1-induced activation of Smad and expression of Snail and Twist was evaluated using Western blot analysis. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 48 h. Cytosolic and Nuclear fractions were obtained. Actin and histone H3 were used as internal control of cytosolic and nuclear fraction, respectively. The relative, normalized ratio between p-Smad2 and actin was presented. 

30683840 25798061 24023938
Immunofluorescence
β-catenin; 

PubMed: 24023938     


Nuclear translocation of β-catenin and its inhibition by CX-4945 were confirmed by immunocytochemistry. Nuclei were counterstained with Hoechst 33342. All scale bars represent 20 µm.

E-cadherin / Vimentin; 

PubMed: 24023938     


The effect of CX-4945 on the TGF-β1-induced expression of epithelial and mesenchymal markers was evaluated by immunocytochemistry. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 72 h. All scale bars represent 200 µm.

24023938
Growth inhibition assay
Cell viability; 

PubMed: 30316146     


CX-4945 decreases cell viability of HuCCT1, EGI-1, and Liv27 CCA cell lines in dose-dependent manner (IC50of 7.3, 9.5, and 9.4 μM, respectively) (A)

30316146
In vivo Oral administration of CX-4945 at 25 mg/kg or 75 mg/kg twice daily displays potent antitumor activity in the BT-474 model, with TGI of 88% and 97%, respectively, and 2 of 9 animals in each group showing more than 50% reduction in tumor size compared with the initial tumor volume. In the BxPC-3 model, CX-4945 treatment at 75 mg/kg twice daily shows 93% TGI with 3 animals having no evidence of tumor remaining at the end of the treatment period. [1] In PC3 xenograft model, administration of CX-4945 at 25 mg/kg, 50 mg/kg, or 75 mg/kg causes tumor growth inhibition with TGI of 19%, 40%, and 86%, respectively. [2]

Protocol

Kinase Assay:[2]
- Collapse

CK2 Kinase Assay:

CX-4945 is added at a volume of 10 μL to a reaction mixture comprising 10 μL of assay dilution buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM β-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM dithiothreitol), 10 μL of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 μL of recombinant human CK2 (ααββ-holoenzyme, 25 ng dissolved in ADB). Reactions are initiated by the addition of 10 μL of ATP solution (90% 75 mM MgCl2, 75 μM ATP (final ATP concentration=15 μM) dissolved in ADB; 10% [γ-33P]ATP (stock 1 mCi/100 μL; 3000 Ci/mM and maintained for 10 minutes at 30 °C. The reactions are quenched with 100 μL of 0.75% phosphoric acid and then transferred to and filtered through a phosphocellulose filter plate. After washing each well five times with 0.75% phosphoric acid, the plate is dried under vacuum for 5 minutes and, following the addition of 15 μL of scintillation fluid to each well, the residual radioactivity is measured using a Wallac luminescence counter. The IC50 values are derived from eight concentrations of CX-4945 over a range of 0.0001 μM to 1 μM.
Cell Research:[1]
- Collapse
  • Cell lines: SKBr3, MDA-MB-453, BT-474, ZR-75-1, MDA-MB-231, MDA-MB-468, T47D, MCF 7, Hs578T, MDA-MB-361, UACC-812, et al.
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 4 days
  • Method: Cells are seeded at a density of 3,000 cells per well 24 hours prior to treatment, in appropriate media, and then treated with various concentrations of CX-4945. Suspensions cells are seeded and treated on the same day. Following 4 days of incubation, Alamar Blue (20 μL, 10% of volume per well) is added and the cells are further incubated at 37 °C for 4-5 hours. Fluorescence with excitation wavelength at 530-560 nm and emission wavelength at 590 nm is measured.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female immunocompromised mice CrTac:Ncr-Foxn1nu injected with BxPC-3 or BT-474 cells
  • Dosages: 25 or 75 mg/kg
  • Administration: Oral gavage twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 16 mg/mL (45.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.77
Formula

C19H12ClN3O2

CAS No. 1009820-21-6
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound (S2248) for in vivo uses?

  • Answer:

    For injection, CX-4945 can be dissolved in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 5mg/ml clearly. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm the solution in water bath at about 45-50℃. Then add PEG and Tween. After they mixed well, dilute with water. For oral gavage, CX-4945 can be dissolved in 1% CMC Na at 30mg/ml as a homogeneous suspension. This is a common formulation for oral gavage, and is convenience to prepare.

Tags: buy Silmitasertib (CX-4945) | Silmitasertib (CX-4945) supplier | purchase Silmitasertib (CX-4945) | Silmitasertib (CX-4945) cost | Silmitasertib (CX-4945) manufacturer | order Silmitasertib (CX-4945) | Silmitasertib (CX-4945) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID